Log In
Print
BCIQ
Print
Print this Print this
 

ASP015K

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionOral janus kinase-1 (JAK-1) inhibitor
Molecular Target Janus kinase-1 (JAK-1)
Mechanism of ActionJanus kinase-1 (JAK-1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$945.0M

$65.0M

$880.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today